Abstract
The purpose of this chapter is to highlight the rich tradition of self-experiments (SEs) with psychoactive substances carried out by scientists and therapists for more than a century. Scientifically inspired controlled SEs dominated until the end of the twentieth century, when ethical requirements minimized controlled SEs and “wild” SEs expanded particularly with the emergence of new psychoactive substances. The review focuses on laughing gas (nitrous oxide), cannabis, cocaine, hallucinogens, entactogens, and dissociative hallucinogens. This is due to the fact that substances that induce “complex” effects such as alteration of space/time experience, ego dissolution, and increased feelings and insights (e.g., hallucinogens, entactogens) represent by far the majority of SEs, whereas SEs with substances inducing “simple” effects such as euphoria, anxiolysis, dissociation, or emotional blunting (e.g., cocaine, opioids) are much rarer or even absent (e.g., benzodiazepines). Complex drug effects are much harder to describe, thus allowing SEs to fulfill a more important function.
SEs with psychoactive drugs appeared to emerge in the mid-eighteenth century, which triggered a long-standing tradition throughout the nineteenth and early twentieth century. SEs have been de facto performed for a variety of reasons, ranging from establishing scientific knowledge and gaining philosophical insights to compensating for personal deficits. Self-experimenters can be divided into two general types. Besides their scientific intentions, “exploratory” self-experimenters intend to expand awareness and insight, whereas “compensatory” self-experimenters might aim for coping with psychiatric symptoms or personality deficits. Scientific limitations of SEs are obvious when compared to double-blind, randomized, placebo-controlled trials. Whereas the former might lead to more “realistic” detailed description of subjective effects, the latter lead to more solid results in respect to objectively measurable “average” effects. Possible adverse effects of SEs were identified that resulted in loss of scientific objectivity and decreased control over substance use and addiction, development of isolation, problematic group dynamics, and “social autism.”
Keywords
- Cannabis
- Cocaine
- Dissociative hallucinogens
- Entactogens
- Hallucinogens
- History of drug use
- Nitrous oxide
- Psychoactive substances
- Self-experiments
This is a preview of subscription content, access via your institution.
Buying options


Abbreviations
- 2C-B:
-
2-(4-Bromo-2,5-dimethoxyphenyl)ethan-1-amine
- 2C-E:
-
2-(4-Ethyl-2,5-dimethoxyphenyl)ethan-1-amine
- 2C-T-2:
-
2-[4-(Ethylsulfanyl)-2,5-dimethoxyphenyl]ethan-1-amine
- 2C-T-7:
-
2-[2,5-Dimethoxy-4-(propylsulfanyl)phenyl]ethan-1-amine
- 2C-T-4:
-
2-[2,5-Dimethoxy-4-(propan-2-ylsulfanyl)phenyl]ethan-1-amine
- 2C-T-21:
-
2-{4-[(2-Fluoroethyl)sulfanyl]-2,5-dimethoxyphenyl}ethan-1-amine
- 5-HO-DMT:
-
3-[2-(Dimethylamino)ethyl]-1H-indol-5-ol
- AM-2201:
-
[1-(5-Fluoropentyl)-1H-indol-3-yl](naphthalen-1-yl)methanone
- LSD:
-
(8β)-N,N-Diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide (d-lysergic acid diethylamide)
- MDA:
-
1-(2H-1,3-Benzodioxol-5-yl)propan-2-amine
- MDE:
-
1-(2H-1,3-Benzodioxol-5-yl)-N-ethylpropan-2-amine
- MDMA:
-
1-(2H-1,3-Benzodioxol-5-yl)-N-methylpropan-2-amine
- MEM:
-
1-(4-Ethoxy-2,5-dimethoxyphenyl)propan-2-amine
- MPPP:
-
1-Methyl-4-phenylpiperidin-4-yl propanoate
- MPTP:
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
References
Abouchedid R, Gilks T, Dargan PI, Archer JRH, Wood DM (2018) Assessment of the availability, cost, and motivations for use over time of the new psychoactive substances-benzodiazepines diclazepam, flubromazepam, and pyrazolam-in the UK. J Med Toxicol 14:134–143
Abramson HA (ed) (1967) The use of LSD in psychotherapy and alcoholism. Bobbs-Merrill, Indianapolis
Alberts L (1921) Einwirkungen des Meskalins auf komplizierte psychische Vorgänge. Dissertation, Heidelberg University, Heidelberg
Alles G (1959) Subjective reactions to phenethylamine hallucinogens. In: Featherstone RM, Simon A (eds) A pharmacologic approach to the study of the mind. C.C. Thomas, Springfield, pp 238–250
Altman LK (1972) Auto-experimentation – an unappreciated tradition in medical science. N Eng J Med 286:346–352
Altman LK (1986) Who goes first? The story of self-experimentation in medicine. Random House, New York
Ameline A, Richeval C, Gaulier JM, Raul JS, Kintz P (2018) Characterization of flunitrazolam, a new designer benzodiazepine, in oral fluid after a controlled single administration. J Anal Toxicol 42:e58–e60
Ammon G, Patterson PGR (1971) Peyote: Zwei verschiedene Ich-Erfahrungen. Dyn Psychiatr 4(Supplement 1):47–71
Anderson GM, Braun G, Braun U, Nichols DE, Shulgin AT (1978) Absolute configuration and psychotomimetic activity. In: Barnett G, Trsic M, Willette R (eds) QuaSAR – quantitative structure–activity relationships. NIDA research monograph, vol 22. United States Department of Health, Education, and Welfare, Washington, pp 8–15
Arnold OH, Hoff H (1953) Untersuchungen über die Wirkungsweise von Lysergsäurediäthylamid. Wien Z Nervenheilkd Grenzgeb 6:129–150
Arthur JD (2008) Peopled darkness: perceptual transformation through Salvia divinorum. iUniverse, New York
Assi S, Gulyamova N, Kneller P, Osselton D (2017) The effects and toxicity of cathinones from the users’ perspectives: a qualitative study. Hum Psychopharmacol 32:e2610
Auwärter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837
Baumann MH, Glennon RA, Wiley JL (2017) Neuropharmacology of new psychoactive substances (NPS). In: The science behind the headlines. Springer, Cham
Becker AM (1949) Zur Psychopathologie der Lysergsäurediäthylamidwirkung. Wiener Z Nervenhk 2:402–407
Beecher HK (1959) Experimentation in man. J Am Med Assoc 169:461–478
Benz E (1989) Halluzinogen-unterstützte Psychotherapie. Medical dissertation, University of Zürich, Zürich
Benzenhöfer U, Passie T (2010) Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin. Addiction 105:1355–1361
Beringer K (1923) Experimentelle Psychosen durch Mescalin. Z ges Neurol Psychiatr 84:426–433
Beringer K (1927) Der Meskalinrausch. Springer, Berlin
Beringer K (1932) Zur Klinik des Haschischrausches. Nervenarzt 5:337–342
Bisbort A (2009) Beatniks: a guide to an American subculture. Greenwood, Westport
Brandt SD, King LA, Evans-Brown M (2014) The new drug phenomenon. Drug Test Anal 6:587–597
Bumke O (1903) Scopolaminum hydrobromicum. Monatsschr Psychiatr Neurol 13:62–69
Caldwell WV (1968) LSD psychotherapy: an exploration of psychedelic and psycholytic therapy. Grove Press, New York
Calton T, Ferriter M, Huband N, Spandler H (2008) A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia. Schizophr Bull 34:181–192
Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3:619–627
Castiglioni A (1947) A history of medicine. Alfred A. Knopf, New York
Cohen S (1964) The beyond within the L.S.D. story. Atheneum, New York, pp 106–111
Cohen S (1967) Discussion. In: Abramson HA (ed) The use of LSD in psychotherapy. Josiah Macy, New York, p 11
Condrau G (1949) Klinische Erfahrungen an Geisteskranken mit Lysergsäure-Diäthylamid. Acta Psychiatr Scand 24:9–32
Crowley A ([1917] 1973) Cocaine. Level Press, San Francisco
Dargan PI, Wood DM (eds) (2013) Novel psychoactive substances. Academic Press, Amsterdam
Davy H (1800) Researches, chemical and philosophical: chiefly concerning nitrous oxide, or diphlogisticated nitrous air, and its respiration. J. Johnson, London
Downing JJ (1965) Zihuatanejo: an experience of transpersonative living. In: Blum R (ed) Utopiates – the use and users of LSD. Tavistock Publications, London, pp 142–178
Dulchinos DP (1999) Fitz Hugh Ludlow: pioneer of inner space. In: Lyttle T (ed) Psychedelics reimagined. Autonomedia, New York, pp 29–40
Ellis H (1898) Mescal, a new artificial paradise. Contemp Theatr Rev 73:131–141
Erowid E, Erowid F (2015) The kratom experience from firsthand reports. In: Raffa RB (ed) The chemistry and pharmacology of opioids from a non-opium source. CRC Press, Boca Raton, pp 213–244
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2015) New psychoactive substances in Europe. An update from the EU early warning system. http://www.emcdda.europa.eu/system/files/publications/65/TD0415135ENN.pdf. Accessed 1 May 2018
Evans-Brown M, Sedefov R (2018) Responding to new psychoactive substances in the European Union: early warning, risk assessment, and control measures. Handb Exp Pharmacol. https://doi.org/10.1007/164_2018_160
Feldman HW, Agar MH, Beschner GM (eds) (1979) Angel dust. An ethnographic study of phencyclidine users. Lexington Books, Lexington
Ferkel S (1954) “Hexensalben” und ihre Wirkung. Kosmos 50:414–415
Fischer R (1946) Selbstbeobachtungen im Meskalinrausch. Schweiz Z Psychol 5:308–313
Fränkel F, Joël E (1927) Beiträge zu einer experimentellen Psychopathologie: der Haschischrausch. Z ges Neurol Psychiatr 111:84–106
Frederking W (1955) Intoxicant drugs (mescaline and lysergic acid diethylamide) in psychotherapy. J Nerv Ment Dis 121:262–266
Freud S (1884) Über Coca. Centralbl ges Ther 2:289–314
Freud S (1885a) Beitrag zur Kenntnis der Coca-Wirkung. Wien Med Wochenschr 5:129–133
Freud S (1885b) Zur Coca-Wirkung beim gesunden Menschen. Centralbl ges Ther 3:253–254
Friedrichs H ([1940] 2009) Die Psychologie des Meskalinrausches. VWB, Berlin
Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202:513–520
Gonzalez D, Riba J, Bouso JC, Gomez-Jarabo G, Barbanoj MJ (2006) Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 85:157–162
Grof S (1964) K problematice optických poruch v autoexperimentech s halucinogeny. Česk Psychiatr 3:173–181
Grof S (1980) LSD psychotherapy. Hunter House, Pomona
Guttmann (1921) Hallluzinationen und andere Folgeerscheinungen nach experimenteller Vergiftung mit Anhalonium (Mescal). Berl Klin Wochenschr 58:816–817
Haldane JS (1922) Respiration. Yale University Press, New Haven
Haldane JS, Smith JL (1893) The physiological effects of air ventilated by respiration. J Pathol Bacteriol 1:168–186
Hearne E, Van Hout MC (2016) “Trip-sitting” in the black hole: a netnographic study of dissociation and indigenous harm reduction. J Psychoactive Drugs 48:233–242
Heffter A (1894) Über Pellote. Arch Exp Pathol Pharmakol 34:65–86
Heffter A (1898) Über Pellote. Zweite Mitteilung. Arch Exp Pathol Pharmakol 40:385–429
Heimann H (1952) Die Scopolaminwirkung. Karger, Basel
Henderson GL (1988) Designer drugs: past history and future prospects. J Forensic Sci 33:569–575
Henderson L, Glass W (eds) (1994) LSD: still with us after all these years. Lexington Books, New York
Hoffer A, Osmond H (1967) The hallucinogens. Academic Press, New York
Hofmann A (1955) The history of LSD-25. Triangle 2:117–124
Hofmann (1979) LSD-mein Sorgenkind. Klett-Cotta, Stuttgart
Hollingshead M (1973) The man who turned on the world. Blond & Briggs, London
Huppertz LM, Moosmann B, Auwärter V (2018) Flubromazolam – basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. Drug Test Anal 10:206–211
Hutter M, Moosmann B, Kneisel S, Auwärter V (2013) Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism. J Mass Spectrom 48:885–894
Huxley A (1954) The doors of perception. Chatto & Windus, London
Huxley A (1980) Moksha. Chatto & Windus, London
James W (1882) Subjective effects of nitrous oxide. Mind 7:186–208
James W (1902) The varieties of religious experience. Longmans, New York
Jansen KL (2000) A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs 32:419–433
Jansen K ([2001] 2004) Ketamine: dreams and realities. MAPS, Sarasota
Jansen KL, Darracot-Cankovic R (2001) The nonmedical use of ketamine, part two: a review of problem use and dependence. J Psychoactive Drugs 33:151–158
Jay M (2009) The atmosphere of heaven. Yale University Press, London
Jöel E, Fränkel F (1924) Der Cocainismus. Ein Beitrag zur Geschichte und Psychopathologie der Rauschgifte. Springer, Berlin
Jöel E, Fränkel F (1926) Der Haschisch-Rausch. Beiträge zu einer experimentellen Psychopathologie. Klin Wochenschr 5:1707–1709
Joël E, Fränkel F (1929) Beiträge zur experimentellen Psychopathologie. Klin Wochenschr 8:549–550
Kant F, Kropf E (1928) Über Selbstversuche mit Haschisch. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 129:319–338
Kelly K (1999) The little book of ketamine. Ronin, Berkeley
Ketchum J (2006) Chemical warfare secrets almost forgotten. Chembooks, Santa Rosa
King LA (2014) New phenethylamines in Europe. Drug Test Anal 6:808–818
King LA, Kicman AT (2011) A brief history of ‘new psychoactive substances’. Drug Test Anal 3:401–403
Kintz P, Richeval C, Jamey C, Ameline A, Allorge D, Gaulier JM, Raul JS (2017) Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism. Drug Test Anal 9:1026–1033
Kirsch MM (1986) Designer drugs. CompCare Publications, Minneapolis
Kjellgren A, Jonsson K (2013) Methoxetamine (MXE) – a phenomenological study of experiences induced by a “legal high” from the internet. J Psychoactive Drugs 45:276–286
Kjellgren A, Soussan C (2011) Heaven and hell – a phenomenological study of recreational use of 4-HO-MET in Sweden. J Psychoactive Drugs 43:211–219
Kjellgren A, Henningsson H, Soussan C (2013) Fascination and social togetherness-discussions about spice smoking on a Swedish internet forum. Subst Abuse 7:191–198
Klinke O (1889) Hyoscin bei Geisteskranken. Z Nervenheilkd Psychopathol 12:189–196
Klüver H (1966) Mescal and mechanisms of hallucinations. University of Chicago Press, Chicago
Klüver H (1980) Foreword. In: Schultes RE, Hofmann A (eds) The botany and chemistry of hallucinogens, 2nd edn. C.C. Thomas, Springflied, pp VII–VVX
Knauer A, Maloney WJ (1913) A preliminary note on the psychic action of mescaline, with special reference to the mechanism of visual hallucinations. J Nerv Ment Dis 40:425–436
Konrad E (1888) Zur physiologischen und therapeutischen Wirkung des Hyoscinum hydrochloricum. Centralbl Nervenheilk 11:529
Langston JW (2017) The MPTP story. J Parkinsons Dis 7:S11–S22
Leary T (1966) Programmed communication during experiences with DMT (dimethyltryptamine). Psychedelic Rev 8:83–95
Leary T, Litwin GH, Metzner R (1963) Reactions to psilocybin administered in a supportive environment. J Nerv Ment Dis 137:561–573
Lewin L (1924) Phantastica. Die betäubenden und erregenden Genussmittel. Für Ärzte und Nichtärzte. Verlag von Georg Stilke, Berlin
Lewin L (1888) Über Anhalonium lewinii. Arch Exp Pathol Pharmakol 24:401–411
Lewin L (1998) Phantastica: a classic survey on the use and abuse of mind-altering plants. Park Street Press, Rochester
Lilly JC (1972a) Programming and metaprogramming in the human biocomputer. Julian Press, New York
Lilly JC (1972b) The center of the cyclone. Julian Press, New York
Lilly JC (1978) The scientist. Crown Publishers, New York
Ludlow F (1857) The Hasheesh eater. Harper & Bros, New York
Mantegazza P (1859 [1973]) Sulle virtu igienische e medicale de la coca. Ann univers di medic Bd. 167:449ff. Partially reprinted. In: Andrews G, Solomon D (eds) The coca leaf and cocaine papers. Harcourt Brace Jovanovich, New York, pp 38–42
Maqueda AE, Valle M, Addy PH, Antonijoan RM, Puntes M, Coimbra J, Ballester MR, Garrido M, Gonzalez M, Claramunt J, Barker S, Johnson MW, Griffiths RR, Riba J (2015) Salvinorin-A induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans. Int J Neuropsychopharmacol 18:pyv065
Matussek N (1952) Wahnsymptome im Meskalinrausch. Medical dissertation, Max-Planck-Institut für Psychiatrie, München
Mayer-Gross W, McAdam W, Walker JW (1951) Psychological and biochemical effects of lysergic acid diethylamide. Nature 168:827–828
McGlothlin W, Cohen S, McGlothlin MS (1967) Long lasting effects of LSD on normals. Arch Gen Psychiatry 17:521–532
McKenna T (1991) The archaic revival. Speculations on psychedelic mushrooms, the amazon, virtual reality, UFOs, evolution, shamanism, the rebirth of the goddess, and the end of history. Harper Collins, San Francisco
Meyer P (1993) Apparent communication with discarnate entities related to DMT. Psychedelic Monogr Essays 6:29–67
Meyer MR (2018) Toxicokinetics of NPS: update 2017. Handb Exp Pharmacol. https://doi.org/10.1007/1164_2018_1102
Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25:439–452
Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B, Michel Y, Brewerton TD, Doblin R (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol 27:28–39
Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, Holland J, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R (2018) 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 5:486–497
Moore M, Alltounian HS (1978) Journeys into the bright world. Para Research, Rockport
Moosmann B, Huppertz Laura M, Hutter M, Buchwald A, Ferlaino S, Auwärter V (2013a) Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics. J Mass Spectrom 48:1150–1159
Moosmann B, Hutter M, Huppertz LM, Ferlaino S, Redlingshöfer L, Auwärter V (2013b) Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. Forensic Toxicol 31:263–271
Moosmann B, Bisel P, Auwärter V (2014) Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test Anal 6:757–763
Morris H, Wallach J (2014) From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal 6:614–632
Mosher L (1999) Lecture on Soteria treatment for psychotic patients. Hannover Medical School, Hannover
Nichols DE (2016) Psychedelics. Pharmacol Rev 68:264–355
Novak SJ (1997) LSD before Leary. Sidney Cohen’s critique of 1950s psychedelic drug research. Isis 88:87–110
Osmond H (1970) Peyote night. In: Aaronson BS, Osmond H (eds) Psychedelics. The Hogarth Press, London, pp 67–86
Oss OT, Oeric ON (1976) Psilocybin – magic mushroom grower’s guide. And/Or Press, Berkeley
Ott J (1994) Ayahuasca analogues–Pangean entheogens. Natural Products, Washington
Ott J (1999) Pharmahuasca: human pharmacology of oral DMT plus harmine. J Psychoactive Drugs 31:171–177
Ott J (2001a) Shamanic snuffs or entheogenic errhines. Entheobotanica, Solothurn
Ott J (2001b) Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. J Psychoactive Drugs 33:273–281
Ott J (2001c) Pharmepéna-psychonautics: human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine. J Psychoactive Drugs 33:403–407
Passie T (1997) Hanscarl Leuner: pioneer of hallucinogen research and psycholytic therapy. Multidiscipl Assoc Psychedelic Stud Bull 7:46–49
Passie T (2002) Protocol for a research study of psilocybin in a clinical setting. Hannover Medical School, Hannover
Passie T (2005) Meskalin in Deutschland 1912–1945: Grundlagenforschung, Selbstversuche und Missbrauch. In: Pieper W (ed) Nazis on speed, vol 2, pp 234–244
Passie T (2018) The early use of MDMA (‘Ecstasy’) in psychotherapy (1977–1985). Drug Sci Policy Law 4:1–19
Passie T, Benzenhöfer U (2016) The history of MDMA as an underground drug in the United States, 1960–1979. J Psychoactive Drugs 48:67–75
Passie T, Benzenhöfer U (2018) MDA, MDMA and other “mescaline-like” substances in the US military’s search for a truth drug (1940s to 1960s). Drug Test Anal 10:72–80
Pickering GW (1949) The place of experimental method in medicine. Proc R Soc Med 42:229–234
Prentiss DW, Morgan FP (1895) Anhalonium lewinii (Mescal buttons): a study of the drug with special reference to its physiological action upon man with report of experiments. Therapeut Gaz 19:577–585
Prinzhorn H (1927) Erdentrückte Seele. Leuchter 8:277–296
Prinzhorn H (1928) Entrückung durch Rauschgift. Zeitsch Parapsychol 55:24–34
Resnikoff C (2018) Mail to Torsten Passie. 6 Apr 2018
Ring FW (1887) Cocaine and its fascinations, from a personal experience. Medical Record, September 3, 1887. In: Andrews G, Solomon D (eds) The coca leaf and cocaine papers, vol 1973. Harcourt Brace Jovanovich, New York, pp 253–258
Roubíček J (1961) Experimentální psychosy. SZdN, Prague
Shedlin M, Wallechinski D, Sayler S (eds) ([1973] 1992) Laughing gas. Ronin, Berkeley
Shulgin AT (1975) Centrally active phenethylamines. Psychopharmacol Commun 1:93–98
Shulgin A, Shulgin A (1991) PIHKAL. Transform Press, Berkeley
Shulgin A, Shulgin A (1997) TIHKAL. Transform Press, Berkeley
Shulgin AT, Shulgin LA, Jacob PA (1986) A protocol for the evaluation of new psychoactive drugs. Methods Find Exp Clin Pharmacol 8:313–320
Siebert DJ (1994) Salvia divinorum and Salvinorin A – new pharmacological findings. J Ethnopharmacol 43:53–56
Simpson ESC, Weiner JA (eds) (1989) The Oxford encyclopaedic English dictionary. Clarendon Press, Oxford
Solms H (1956) Relationships between chemical structure and psychoses with the use of psychotoxic substances. “Comparative pharmacopsychiatric analysis”: a new research method. J Clin Exp Psychopathol 17:429–433
Solomon D (1964) Editor’s preface. In: Solomon D (ed) LSD – the consciousness-expanding drug. Putnam’s, New York, pp IX–IX
Soussan C, Kjellgren A (2014) Harm reduction and knowledge exchange – a qualitative analysis of drug-related internet discussion forums. Harm Red J 11:25–33
Soussan C, Kjellgren A (2015) “Chasing the high” – experiences of ethylphenidate as described on international internet forums. Subst Abuse 9:9–16
Soussan C, Andersson M, Kjellgren A (2018) The diverse reasons for using novel psychoactive substances – a qualitative study of the users’ own perspectives. Int J Drug Policy 52:71–78
Stafford P (1990) Magic grams: investigations into psychedelic consciousness with Dr. Oscar Janiger. Psychedelic Monogr Essays 5
Stolaroff M (1994) Thanatos to Eros: thirty-five years of psychedelic exploration. VWB, Berlin
Stolaroff M (2004) The secret chief revealed. MAPS, Sarasota
Stoll WA (1947) Lysergsäure-diäthylamid, ein Phantastikum aus der Mutterkorngruppe. Schweiz Arch Neurol Psychiat 60:279–280
Styk J (1994) Rückblick auf die letzten sieben Jahre der Schweizerischen Ärztegesellschaft für Psycholytische Therapie (SÄPT). In: Dittrich A, Hofmann A, Leuner H (eds) Welten des Bewusstseins, vol 4. VWB, Berlin, pp 149–154
Swogger MT, Hart E, Erowid F, Erowid E, Trabold N, Yee K, Parkhurst KA, Priddy BM, Walsh Z (2015) Experiences of Kratom users: a qualitative analysis. J Psychoactive Drugs 47:360–367
Szára S (1957) The comparison of the psychotic effect of tryptamine derivatives with the effects of mescaline and LSD-25 in self-experiments. In: Garattini S, Ghetti V (eds) Psychotropic drugs. Elsevier, Amsterdam, pp 460–467
Szára S (1961) Hallucinogenic effects and metabolism of tryptamine derivatives in man. Fed Proc 20:885–888
Tettey JNA, Crean C, Ifeagwu SC, Raithelhuber M (2018) Emergence, diversity and control of new psychoactive substances – a global perspective. Handb Exp Pharmacol. https://doi.org/10.1007/164_2018_XXX
Trachsel D (2011) Psychedelische chemie. Nachtschatten Verlag, Solothurn
Trachsel D (2012) Fluorine in psychedelic phenethylamines. Drug Test Anal 4:577–590
Trachsel D, Lehmann D, Enzensperger C (2013) Phenethylamine: Von der Struktur zur Funktion. Nachtschatten Verlag, Solothurn
Turner DM (1996) Salvinorin – the psychedelic essence of Salvia divinorum. Panther Press, San Francisco
United Nations Office on Drugs and Crime (UNODC) (2018) Understanding the synthetic drug market: the NPS factor. https://www.unodc.org/documents/scientific/Global_Smart_Update_2018_Vol.19.pdf. Accessed 29 May 2018
Valdes LJ, Diaz JL, Paul AG (1982) Ethnopharmacology of Ska Maria Pastora (Salvia divinorum Epling and Jativa-M.). J Ethnopharmacol 7:287–312
Van Dusen W (1961) LSD and the enlightenment of Zen. Psychologia 4:11–16
Van Hout MC (2014) An internet study of user’s experiences of the synthetic cathinone 4-methylethcathinone (4-MEC). J Psychoactive Drugs 46:273–286
Van Hout MC, Hearne E (2015a) “Plant or poison”: a netnographic study of recreational use of 1,3-dimethylamylamine (DMAA). Int J Drug Policy 26:1279–1281
Van Hout MC, Hearne E (2015b) “Word of mouse”: indigenous harm reduction and online consumerism of the synthetic compound methoxphenidine. J Psychoactive Drugs 47:30–41
Wagmann L, Maurer HH (2018) Bioanalytical methods for new psychoactive substances. Handb Exp Pharmacol. https://doi.org/10.1007/1164_2017_1083
Waser PG (1990) Psychiatrie, psychopharmaka und drogen in Zürich. Kommissionsverlag Beer AG, Zürich
Wasson RG (1962) Salvia divinorum – a new psychotropic drug from the mint family. Bot Mus Leafl Harvard Univ 20:77–84
Weil A (1976) MDA – the love drug. J Psychedelic Drugs 8:335–337
Weil A (1980) The marriage of the sun and the moon. Houghton Mifflin, Boston
Weir Mitchell S (1896) Remarks on the effects of Anhelonium lewinii (the mescal button). Br Med J 2:1625–1629
Wellen BJ (1986) Zur Geschichte des Bilsenkrautes. Dissertation, Fachbereich Pharmazie Philipps-Universität Marburg, Marburg
Weyl B (1951) Versuch einer psychopathologischen analyse der LSD-Wirkung. Medical dissertation, Albert-Ludwig-University Freiburg, Freiburg im Breisgau
Widmer S (1997) Ins Herz der Dinge Lauschen, 2nd edn. Nachtschatten, Solothurn
Winkler P, Csémy L (2014) Self-experimentations with psychedelics among mental health professionals: LSD in the former Czechoslovakia. J Psychoactive Drugs 46:11–19
Wood HC Jr (1869) On the medical activity of the hemp plant as grown in North America. Proc Am Philos Soc 11:226–232
Zucker K (1926) Die pharmakologische Betrachtungsweise als Forschungsmethode in der Neurologie und Psychiatrie. Klin Wochenschr 5:1977–1779
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Passie, T., Brandt, S.D. (2018). Self-Experiments with Psychoactive Substances: A Historical Perspective. In: Maurer, H., Brandt, S. (eds) New Psychoactive Substances . Handbook of Experimental Pharmacology, vol 252. Springer, Cham. https://doi.org/10.1007/164_2018_177
Download citation
DOI: https://doi.org/10.1007/164_2018_177
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-10560-0
Online ISBN: 978-3-030-10561-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)